Royal Bank Of Canada Relmada Therapeutics, Inc. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

A detailed history of Royal Bank Of Canada transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 1,490 shares of RLMD stock, worth $4,321. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,490

Previous 2,865 47.99%

Holding current value

$4,321

Previous $8,000 50.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.3 - $4.36 $3,162 - $5,995	-1,375 Reduced 47.99%	1,490 $4,000
Q2 2024 Aug 14, 2024	BUY	$2.93 - $4.94 $8,394 - $14,153	2,865 New	2,865 $8,000
Q4 2023 Feb 14, 2024	BUY	$2.45 - $4.22 $8,739 - $15,052	3,567 Added 610.79%	4,151 $17,000
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $1,259 - $1,925	-508 Reduced 46.52%	584 $1,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $1,176 - $1,876	-530 Reduced 32.68%	1,092 $2,000
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $19,418 - $41,264	-8,669 Reduced 84.24%	1,622 $3,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $7,883 - $130,206	3,633 Added 54.57%	10,291 $35,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $3,184 - $6,441	174 Added 2.68%	6,658 $246,000
Q2 2022 Aug 15, 2022	SELL	$16.5 - $30.34 $22,638 - $41,626	-1,372 Reduced 17.46%	6,484 $123,000
Q1 2022 May 16, 2022	SELL	$16.72 - $26.99 $28,106 - $45,370	-1,681 Reduced 17.63%	7,856 $212,000
Q4 2021 Feb 14, 2022	SELL	$16.93 - $26.82 $4,638 - $7,348	-274 Reduced 2.79%	9,537 $215,000
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $6,208 - $9,874	284 Added 2.98%	9,811 $257,000
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $281,522 - $372,982	9,527 New	9,527 $305,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $83M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Relmada Therapeutics, Inc. Transaction History